Phoenix Biotech Acquisition (PBAXW) Financials

$0.03

$-0.05 (-64.29%)

As on 14-Feb-2024 17:56EDT

Market cap

$-- Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	0.25	0.25	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	0.25	0.25	--	--	--	--
Operating Expenses	3.85	2.91	0.33	--	--	--
Operating Profit (EBIT)	-1.33	-0.07	-0.33	--	--	--
Other Income	--	--	--	--	--	--
Profit before Tax	-1.91	-0.07	-0.33	--	--	--
Provision for Tax	0.50	0.60	-0.02	--	--	--
Profit after Tax (Net Income)	-2.41	-0.67	-0.32	--	--	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	--

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	-5.48	2.47	170.83	--	--	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	9.15	9.15	9.15	--	--	--
Current Liabilities	4.80	30.75	0.10	--	--	--
Total Liabilities	13.27	42.37	180.08	--	--	--

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	--	--	178.72	--	--	--
Current Assets	8.47	42.37	1.36	--	--	--
Total Assets	13.27	42.37	180.08	--	--	--
Total Debt*	1.40	0.65	--	--	--	--
Net Current Assets	3.67	11.62	1.26	--	--	--

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-1.09	-0.70	--	--	--
Cash Flow from Investing Activities	--	--	--	--	--	--
Cash from Financing Activities	--	-138.70	180.30	--	--	--
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-0.33	-0.03	--	--	--	--
Cash EPS ($)	--	-0.03	--	--	--	--
Adjusted Book Value ($)	--	0.11	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.05	--	--	--	--
Free Cash Flow per Share ($)	--	-0.05	--	--	--	--

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-0.77	--	--	--	--
ROE (%)	--	-0.77	--	--	--	--
ROA (%)	-2.47	-0.60	--	--	--	--
EBIT Margin (%)	-521.20	-26.91	--	--	--	--
Net Margin (%)	-944.78	-262.03	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	100.00	79.38	--	--	--	--
Net Profit Growth (%)	100.00	-111.61	--	--	--	--
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	-111.67	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-1.48	--	--	--	--
Price / Book Value	--	0.40	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	--	-0.20	3.31	--	--	--
Close Price ($)	0.07	0.04	0.42	--	--	--
High Price ($)	0.12	0.49	0.58	--	--	--
Low Price ($)	0.01	0.01	0.42	--	--	--
Market Cap ($ Cr)	--	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	0.26	--	--	--	--
Short term debt to equity ratio	-0.25	0.26	--	--	--	--
Current Ratio	1.76	1.38	13.88	--	--	--
Quick Ratio	1.76	--	--	--	--	--
Interest Coverage	-8.06	--	--	--	--	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	0.00	0.00	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.